Abstract

Secretion of the intestinal proglucagon-derived peptides (PGDPs) including the incretin glucagon-like peptide-1 (GLP-1) is regulated, at least in part, by the duodenal hormone glucose-dependent insulinotropic peptide (GIP) through a protein kinase (PK) A-dependent pathway. It has been demonstrated that the activation of PKA increases the synthesis of some intestinal PGDPs, particularly the glucagon-like immunoreactive (GLI) peptides glicentin and oxyntomodulin. However, the effects of GIP on GLI and GLP-1 synthesis are not known. Fetal rat intestinal cells in culture were therefore treated for up to 24 h with 5MM: dbcAMP or 10(-6) M: GIP and the changes in glicentin, oxyntomodulin, GLP-1(x-37) and GLP-1(x-36NH2) secretion and synthesis were examined by RIA and HPLC. Both dbcAMP and GIP increased the acute (2 h; to 224±21 and 256±20% of controls, respectively,P<0.001) and chronic (24 h; to 230±22 and 130±6% of controls, respectively,P<0.001) secretion of intestinal PGDPs. In contrast, the total culture content of PGDPs was increased only after 24 h of incubation (to 156±15 and 125±7% of controls for dbcAMP and GIP, respectively,P<0.01). HPLC analysis confirmed that the intestinal cultures produced the GLI peptides glicentin and oxyntomodulin, as well as the biologically active forms of GLP-1, GLP-7(7-37) and GLP-1(7-36NH2). The relative proportion of these peptides was not altered by treatment with dbcAMP or GIP. Thus, in addition to its effects on GLP-1 release from the rat intestine, GIP appears to be an important regulator of the synthesis of this insulinotropic peptide.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call